Connect with us

Company News

Lupin’s Inhalation Research Center, Florida Receives EIR From U.S. FDA

Pharma major Lupin Limited (Lupin) today announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its Inhalation Research Center located at Coral Springs, Florida. The facility was inspected by the U.S. FDA, between February 19, 2020 and February 26, 2020, on behalf of the U.K. MHRA for Lupin’s generic Fostair application to the U.K. MHRA.

Lupin’s Inhalation Research Center at Coral Springs, Florida, inaugurated in August 2015, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

Commenting on the receipt of the EIR, Vinita Gupta, CEO, Lupin said, “The Inhalation Research Center at Florida was established to develop quality respiratory products to benefit patients across the U.S. and other advanced markets. The receipt of the EIR with satisfactory VAI status validates our commitment towards ensuring the highest levels of quality and CGMP compliance at all our sites. We are grateful for the U.S. FDA’s confidence in our team during this critical juncture in the fight against COVID-19, when it has become imperative that we focus on bringing high quality respiratory products to market.”

Shares of LUPIN LTD. was last trading in BSE at Rs.547 as compared to the previous close of Rs. 558.15. The total number of shares traded during the day was 91814 in over 3314 trades.

The stock hit an intraday high of Rs. 593.2 and intraday low of 542.85. The net turnover during the day was Rs. 51762495.-Equity Bulls

Copyright © 2024 Medical Buyer

error: Content is protected !!